当前位置: 首页 >> 检索结果
共有 9440 条符合本次的查询结果, 用时 2.7209498 秒

101. Advancing together: introducing our new editorial board structure.

作者: Franco Scaldaferri.;Loris R Lopetuso.
来源: Minerva Gastroenterol (Torino). 2025年71卷2期81-82页

102. Sex-specific adverse effects of lipid accumulation products and cardiometabolic indices on the prevalence of gallstones: insights from the 2017-2020 national health and nutrition examination survey.

作者: Yangyang Zheng.;Xiaoli Chen.;Yunpeng Ge.;Haowei Shi.;Shiqi Guo.;Wendan Tan.;Jinghai Song.
来源: BMC Gastroenterol. 2025年25卷1期529页
Anthropometric measurements and lipid profiles are associated with the onset of gallstone disease, with these associations exhibiting sex-specific variations. This study investigated the association between the prevalence of gallstones and two anthropometric-lipid markers, namely Lipid Accumulation Products (LAP) and Cardiometabolic Index (CMI), while also assessing the presence of sex disparities.

103. Global burden of esophageal diseases: a comprehensive analysis of disease trends and risk factors from 1990 to 2021.

作者: Yanbin Wei.;Endian Liu.;Jiafei Peng.;Yanqing Liu.;Xiujing Sun.;Xin Yao.
来源: BMC Gastroenterol. 2025年25卷1期528页
Esophageal diseases (ED) are a common category of upper gastrointestinal disorders, mainly including gastroesophageal reflux disease (GERD), esophagitis, Barrett's esophagus, achalasia, and esophageal cancer (EC). In recent years, the high recurrence rate of GERD and poor prognosis of EC are paid more attention, collectively contributing to the global burden of ED.

104. Development and validation of predictive models for disease-free survival and overall survival in non-metastatic right-sided colon adenocarcinoma patients based on inflammatory and nutritional indices.

作者: Yifan Zhang.;Yun Zhou.;Chengjun Wu.;Cheng Ma.
来源: BMC Gastroenterol. 2025年25卷1期527页
This study developed and validated prognostic nomograms incorporating inflammatory and nutritional biomarkers to predict disease-free survival (DFS) and overall survival (OS) in patients with non-metastatic right-sided colon adenocarcinoma (NRCA).

105. The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was independent of intratumoral vascularization.

作者: Tomomi Yasue.;Reiko Ashida.;Ryoji Takada.;Kenji Ikezawa.;Kazuyoshi Ohkawa.;Shigenori Nagata.;Teruki Teshima.;Hirofumi Akita.;Hidenori Takahashi.;Yuichiro Doki.;Hidetoshi Eguchi.
来源: BMC Gastroenterol. 2025年25卷1期526页
Contrast-enhanced harmonic endoscopic ultrasound (CH-EUS) has promising potential in the diagnosis of pancreatic tumors, assessment of fibrosis, and prediction of chemotherapy efficacy. We hypothesize that radiation therapy might reduce variations in chemotherapeutic efficacy caused by fibrosis-induced blood flow disparities, as we explored the relationship between CH-EUS patterns and the efficacy of neoadjuvant chemoradiotherapy (NACRT) in resectable pancreatic cancer (PC).

106. Risk-Adapted Starting Ages for Colorectal Cancer Screening Based on Comprehensive Family History.

作者: Teresa Seum.;Michael Hoffmeister.;Hermann Brenner.
来源: Gastroenterology. 2025年

107. The effectiveness of combining ursodeoxycholic acid with vitamin D in treating patients with primary biliary cholangitis and its impact on hepatic fibrosis: a randomized trial.

作者: Yilihamu Abulitifu.;Mierzhati Maimaiti.;Fengcong Zhao.;Munire Adilijiang.;Wen Qian.;Yongping Zhang.
来源: BMC Gastroenterol. 2025年25卷1期525页
To investigate the effectiveness of combining ursodeoxycholic acid (UDCA) and vitamin D (VitD) in treating patients with primary biliary cholangitis (PBC) and its impact on hepatic fibrosis.

108. Platelet-derived growth factor receptor-β as a non-invasive biomarker for liver fibrosis prediction in Egyptian diabetic patients with metabolic-associated fatty liver disease.

作者: Hanaa Badran.;Maha Elsabaawy.;Mai Magdy.;Hazem Omar.;Olfat Hendy.;Eman Awaad.;Maymona Abd El-Wahed Al-Khalifa.;Mai Abozeid.
来源: BMC Gastroenterol. 2025年25卷1期524页
Circulating platelet-derived growth factor receptor-β (PDGFRβ) has recently been found to correlate with severity of liver disease in multiple etiologies, including liver steatosis. In diabetic patients with metabolic-associated fatty liver disease (MAFLD), widely used non-invasive scoring systems, particularly the fibrosis-4 (FIB-4) score, showed unsatisfactory performance in predicting liver fibrosis severity. The aim of this study was to evaluate the productivity of serum PDGFRβ as a non-invasive biomarker of liver fibrosis in diabetic MAFLD patients.

109. Interferon therapy for chronic hepatitis B virus infection affects nucleoside metabolism: a metabolomics study.

作者: Xiangyang Ye.;Rongxian Qiu.;Xiongzhi He.;Zhenting Hu.;Fengfeng Zheng.;Xiaogang Huang.;Xuemei Xie.;Feihua Chen.;Hanbing Ou.
来源: BMC Gastroenterol. 2025年25卷1期523页
Pegylated interferon alfa (pegIFN-α) is one of the main therapeutic strategies for chronic hepatitis B (CHB) infection. Although interferon-based treatment strategies have great potential in combating CHB, they have significant side effects, and many patients do not respond. In this study, nontargeted metabolomics was performed to investigate the effects of interferon therapy on metabolites and their correlations with clinical indicators. Each group of 20 patients received PEG-IFN alfa-2b for 0, 1, 3, or 6 months. At the end of the IFN-α treatment, patient serum samples were processed for clinical, biological, and metabolomic analyses. The results revealed that in all four groups, the most affected metabolic pathways were ABC transporter, caffeine metabolism, and protein digestion and absorption. Notably, among the top 8 differentially abundant metabolites with high ROC AUC values (≥ 0.95), three were related to pyrimidine nucleoside metabolites (cytidine, 3-methyluridine and ribothymidine), indicating the pivotal role of altered nucleoside metabolism in HBV infection and suggesting that IFN-α treatment might partially correct this dysregulation. The top 20 metabolites were strongly associated with clinical indicators, with significant differences after IFN-α treatment, and may serve as promising biomarkers for monitoring HBV progression and the therapeutic effect of IFN-α treatment for chronic HBV infection.

110. Early acetaminophen administration and mortality outcomes in critically ill patients with cirrhosis: a retrospective analysis from the MIMIC-IV database.

作者: Xiao-Fei Fan.;Shao-Kang Xu.;Shen-Ao Fu.;Xuan He.;Jia-Kai Fang.;Wen Gao.;Na Guo.
来源: BMC Gastroenterol. 2025年25卷1期522页
Cirrhosis is a major global health burden, often requiring ICU admission due to complications. Acetaminophen (APAP) is frequently used for pain and fever management in critically ill patients, but its safety in cirrhotic patients remains uncertain.

111. Neonatal intrahepatic cholestasis caused by citrin deficiency: clinical features, genetic characteristics, and treatment outcomes.

作者: Yigui Zou.;Yu Dai.;Liang Liu.;Qinghua Yang.;Wenwen Li.;Yilin Dong.;Sicong Li.;Yongwei Cheng.;Dongling Dai.
来源: BMC Gastroenterol. 2025年25卷1期519页
Neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) is an autosomal recessive disorder with heterogeneous clinical manifestations. This study aimed to characterize the clinical, biochemical, and genetic spectrum of NICCD and evaluate treatment outcomes.

112. Predictive role of the Albumin-Bilirubin score in ICU patients with cirrhosis and sepsis: insights from a large retrospective cohort.

作者: Jianjun Wang.;Pei Yang.;Chuan Qin.;Yongwei Huang.;Zhaohui Hu.;Ruizi Shi.;Sirui Chen.;Xi Chen.;Hua Luo.;Jianping Gong.;Xintao Zeng.;Decai Wang.
来源: BMC Gastroenterol. 2025年25卷1期520页
The albumin-bilirubin (ALBI) score is a valuable prognostic tool for diseases such as hepatocellular carcinoma, heart failure, and acute kidney injury. However, its association with the prognosis of patients with liver cirrhosis and sepsis in the intensive care unit (ICU) remains unclear.

113. Impacts of salt restriction on nutritional status, sarcopenia, and mortality of cirrhotic patients with ascites.

作者: Maha Elsabaawy.;Mohammed Ragab.;Madiha Naguib.;Eman Kamal.;Maymona Al-Khalifa.;Khaled Gamil.;Marwa Elfayoumy.
来源: BMC Gastroenterol. 2025年25卷1期521页
Salt restriction is a cornerstone in managing ascites in cirrhotic patients; however, its impact on nutritional status, sarcopenia, and mortality remains unclear.

114. Combined association of chewing capacity and depression with constipation: a cross-sectional study.

作者: Jian-Fei Huang.;Yu-Jun Xiong.;Xiang-Da Meng.;Tian Lv.
来源: BMC Gastroenterol. 2025年25卷1期517页
This study aimed to investigate the independent and combined effects of chewing capacity and depression on the risk of constipation, using data from the National Health and Nutrition Examination Survey (NHANES) 2005-2010.

115. Machine learning survival models for Non-alcoholic fatty liver disease based on a health checkup cohort.

作者: Hongyu Zhang.;Li Zhang.;Na Li.;Yongsheng Zhang.;Xiaowen Zhang.;Dawei Wang.
来源: BMC Gastroenterol. 2025年25卷1期518页
This study aimed to develop an accurate prediction model for the risk of Non-alcoholic fatty liver disease (NAFLD) using the random survival forests (RSF), and to investigate the distribution of NAFLD risk with time.

116. Irisin prevents liver injury during exhausting physical activity by suppressing ferroptosis via Nrf2/GPX4 signaling.

作者: Zhenyu Li.;Beile Wang.;Xinyu Li.
来源: BMC Gastroenterol. 2025年25卷1期516页
Irisin, a recently identified protein that is released during exercise and promotes the transformation of white adipocytes into brown adipocytes. The expression of irisin in the liver suggests its possible involvement in liver function and performance, however it has not been comprehensively investigated.

117. Diagnosis model for gastric submucosal tumor based on multiple decision trees comprising endoscopic and endoscopic ultrasonography features.

作者: Shen Su.;Shun-Yao Wu.;Yun-He Tang.;Lin-Lin Ren.;Fan Yin.;Yu-Shuang Xu.;Xiao-Yu Li.;Hua Liu.;Shao-Hua Zhang.;Xing-Lin Zhang.;Zi-Bin Tian.;Tao Mao.
来源: BMC Gastroenterol. 2025年25卷1期515页
The clinical course and manifestations of subepithelial lesions (SEL) patients tend to vary from different pathological types, therefore the accurate diagnosis of SEL would undoubtedly be beneficial to the treatment and prognosis of SEL patients. Based on the decision tree method, we developed a novel classification model for SELs by combining endoscopy with endoscopic ultrasound (EUS).

118. The prognostic value of immunoscore in the early-onset colorectal cancer.

作者: Xinchun Wu.;Sen Hou.;Yingjiang Ye.;Zhidong Gao.
来源: BMC Gastroenterol. 2025年25卷1期513页
The purpose of this study was to explore the prognostic value of Immunoscore in patients with early-onset colorectal cancer.

119. Prognostic value of the international normalized ratio to albumin ratio in acute pancreatitis: insights from MIMIC-IV database.

作者: XingYi Yang.;Yi Ying.;Min Zhang.;LiHong Lv.;XiaoXiao Wang.;JunWei Fang.
来源: BMC Gastroenterol. 2025年25卷1期511页
While the prognostic value of the international normalized ratio - to - albumin ratio (PTAR) has been established in several diseases, its predictive value in acute pancreatitis (AP) mortality remains uncertain. This study aimed to investigate the association between PTAR and survival outcomes in AP patients.

120. MRI findings of confluent hepatic fibrosis caused by different etiologies.

作者: Dan Yu.;Xiao-Hua Li.;Xue-Lin He.;Xi-Bin Jia.;Zhen-Chang Wang.;Zheng-Han Yang.;A-Hong Ren.
来源: BMC Gastroenterol. 2025年25卷1期512页
To identify the magnetic resonance imaging (MRI) features of confluent hepatic fibrosis (CHF) caused by different etiologies.
共有 9440 条符合本次的查询结果, 用时 2.7209498 秒